Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Meulenbeld HJ, van Werkhoven ED, Coenen JL, Creemers GJ, Loosveld OJ, de Jong PC, Ten Tije AJ, Fosså SD, Polee M, Gerritsen W, Dalesio O, de Wit R. Meulenbeld HJ, et al. Eur J Cancer. 2012 Nov;48(16):2993-3000. doi: 10.1016/j.ejca.2012.05.014. Epub 2012 Jun 6. Eur J Cancer. 2012. PMID: 22677260 Free article. Clinical Trial.
AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.
Sieuwerts AM, Onstenk W, Kraan J, Beaufort CM, Van M, De Laere B, Dirix LY, Hamberg P, Beeker A, Meulenbeld HJ, Creemers GJ, van Weerden WM, Jenster GW, Nieuweboer AJM, Mathijssen RHJ, de Wit R, Martens JWM, Sleijfer S. Sieuwerts AM, et al. Among authors: meulenbeld hj. Mol Oncol. 2019 Aug;13(8):1795-1807. doi: 10.1002/1878-0261.12529. Epub 2019 Jun 28. Mol Oncol. 2019. PMID: 31180178 Free PMC article. Clinical Trial.
Circulating Tumor Cell Enumeration and Characterization in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Cabazitaxel.
de Kruijff IE, Sieuwerts AM, Onstenk W, Kraan J, Smid M, Van MN, van der Vlugt-Daane M, Hoop EO, Mathijssen RHJ, Lolkema MP, de Wit R, Hamberg P, Meulenbeld HJ, Beeker A, Creemers GJ, Martens JWM, Sleijfer S. de Kruijff IE, et al. Among authors: meulenbeld hj. Cancers (Basel). 2019 Aug 20;11(8):1212. doi: 10.3390/cancers11081212. Cancers (Basel). 2019. PMID: 31434336 Free PMC article.
Hepatosplenic gammadelta T-cell lymphoma: A case report.
Meulenbeld HJ, Spiering W, Nooijen P, Peters W, Creemers GJ. Meulenbeld HJ, et al. Eur J Intern Med. 2007 May;18(3):241-3. doi: 10.1016/j.ejim.2006.09.027. Eur J Intern Med. 2007. PMID: 17449399
Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.
Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R. Meulenbeld HJ, et al. BJU Int. 2013 Jan;111(1):44-52. doi: 10.1111/j.1464-410X.2012.11404.x. Epub 2012 Aug 29. BJU Int. 2013. PMID: 22928785 Clinical Trial.
Danusertib, an aurora kinase inhibitor.
Meulenbeld HJ, Mathijssen RH, Verweij J, de Wit R, de Jonge MJ. Meulenbeld HJ, et al. Expert Opin Investig Drugs. 2012 Mar;21(3):383-93. doi: 10.1517/13543784.2012.652303. Epub 2012 Jan 13. Expert Opin Investig Drugs. 2012. PMID: 22242557 Review.
15 results